CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 80 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $5,954,095 | +25.6% | 543,753 | 0.0% | 7.06% | -28.5% |
| Q1 2023 | $4,741,526 | +39.1% | 543,753 | 0.0% | 9.88% | +40.1% |
| Q4 2022 | $3,409,330 | +79.2% | 543,753 | 0.0% | 7.06% | +117.5% |
| Q3 2022 | $1,903,000 | +18.6% | 543,753 | 0.0% | 3.24% | +31.9% |
| Q2 2022 | $1,604,000 | -5.1% | 543,753 | 0.0% | 2.46% | +45.7% |
| Q1 2022 | $1,691,000 | -8.0% | 543,753 | 0.0% | 1.69% | +71.7% |
| Q4 2021 | $1,838,000 | -7.4% | 543,753 | 0.0% | 0.98% | +19.6% |
| Q3 2021 | $1,985,000 | -16.3% | 543,753 | 0.0% | 0.82% | +4.6% |
| Q2 2021 | $2,371,000 | -4.0% | 543,753 | 0.0% | 0.79% | +63.4% |
| Q1 2021 | $2,469,000 | -20.9% | 543,753 | 0.0% | 0.48% | +48.5% |
| Q4 2020 | $3,121,000 | -20.7% | 543,753 | 0.0% | 0.32% | -55.1% |
| Q3 2020 | $3,937,000 | -99.8% | 543,753 | 0.0% | 0.72% | +164.1% |
| Q2 2020 | $1,897,697,000 | +135.8% | 543,753 | 0.0% | 0.27% | +23.5% |
| Q1 2020 | $804,754,000 | -24.5% | 543,753 | 0.0% | 0.22% | -31.2% |
| Q4 2019 | $1,065,755,000 | -61.7% | 543,753 | 0.0% | 0.32% | -70.2% |
| Q3 2019 | $2,784,014,000 | -28.5% | 543,753 | 0.0% | 1.08% | -5.0% |
| Q2 2019 | $3,893,270,000 | -73.0% | 543,753 | -49.9% | 1.13% | -76.2% |
| Q1 2019 | $14,442,063,000 | +69.2% | 1,084,696 | 0.0% | 4.76% | +12.6% |
| Q4 2018 | $8,536,555,000 | -29.0% | 1,084,696 | 0.0% | 4.23% | +3.4% |
| Q3 2018 | $12,018,432,000 | -14.6% | 1,084,696 | +3.4% | 4.09% | -6.9% |
| Q2 2018 | $14,072,225,000 | +3.3% | 1,048,601 | 0.0% | 4.39% | +0.8% |
| Q1 2018 | $13,621,327,000 | +41.2% | 1,048,601 | 0.0% | 4.36% | -57.1% |
| Q4 2017 | $9,647,127,000 | +16.8% | 1,048,601 | 0.0% | 10.15% | +61.4% |
| Q3 2017 | $8,262,974,000 | +36.8% | 1,048,601 | 0.0% | 6.29% | +32.4% |
| Q2 2017 | $6,039,940,000 | +34.0% | 1,048,601 | 0.0% | 4.75% | +44.9% |
| Q1 2017 | $4,508,983,000 | +148.6% | 1,048,601 | 0.0% | 3.28% | +85.7% |
| Q4 2016 | $1,814,080,000 | -10.8% | 1,048,601 | 0.0% | 1.77% | -22.1% |
| Q3 2016 | $2,034,286,000 | +11.5% | 1,048,601 | 0.0% | 2.27% | +22.7% |
| Q2 2016 | $1,824,566,000 | +28.9% | 1,048,601 | 0.0% | 1.85% | +80.9% |
| Q1 2016 | $1,415,611,000 | -20.1% | 1,048,601 | 0.0% | 1.02% | -1.4% |
| Q4 2015 | $1,772,135,000 | -12.9% | 1,048,601 | 0.0% | 1.04% | -11.1% |
| Q3 2015 | $2,034,285,000 | -27.9% | 1,048,601 | 0.0% | 1.17% | -67.4% |
| Q2 2015 | $2,820,736,000 | -61.1% | 1,048,601 | 0.0% | 3.58% | -43.9% |
| Q1 2015 | $7,256,319,000 | -29.6% | 1,048,601 | 0.0% | 6.38% | -35.2% |
| Q4 2014 | $10,307,748,000 | – | 1,048,601 | – | 9.86% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |